| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jennifer Michaelson | Chief Scientific Officer | 2026-05-05 | 4,000 | $4.30 | $17.20kBuy |
| Jennifer Michaelson | Chief Scientific Officer | 2026-05-05 | 200 | $15.58 | $3.12kSell |
| Jennifer Michaelson | Chief Scientific Officer | 2026-05-05 | 7,800 | $14.60 | $113.88kSell |
| Jennifer Michaelson | Chief Scientific Officer | 2026-03-05 | 8,000 | $15.68 | $125.44kSell |
| Jennifer Michaelson | Chief Scientific Officer | 2026-03-05 | 4,000 | $4.30 | $17.20kBuy |
| Jennifer Michaelson | Chief Scientific Officer | 2026-02-25 | 1,780 | $14.14 | $25.17kSell |
| Nadim Ahmed | President and CEO | 2026-02-24 | 13,515 | $14.47 | $195.56kSell |
| Jeffrey Alan Jones | Chief Medical Officer | 2026-02-24 | 4,582 | $14.47 | $66.30kSell |
| Jacquelyn L. Sumer | Chief Legal Officer | 2026-02-24 | 3,601 | $14.47 | $52.11kSell |
| Jennifer Michaelson | Chief Scientific Officer | 2026-02-24 | 3,601 | $14.47 | $52.11kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ansbert Gadicke | 26.70% | 16,157,644 | $242.20M | Insider |
| Lynx1 Capital Management LP | 14.81% | 8,963,500 | $134.36M | Insider |
| Lynx1 Capital Management LP | 14.81% | 8,963,500 | $134.36M | Institution |
| Mpm Bioimpact LLC | 12.64% | 7,648,268 | $114.65M | Institution |
| Ubs Oncology Impact Fund LP | 12.64% | 7,648,268 | $114.65M | Insider |
| Bvf Inc | 9.50% | 5,750,683 | $86.20M | Institution |
| Morana Jovanembiricos | 7.65% | 4,631,022 | $69.42M | Insider |
| Vision Scs F2 | 7.40% | 4,476,350 | $67.10M | Insider |
| F2 Bioscience I 2017 Ltd | 7.32% | 4,430,964 | $66.42M | Insider |
| Blackrock Inc | 7.27% | 4,400,296 | $65.96M | Institution |